Trial Profile
Demonstrate the lot-to-lot consistency of 3 consecutive production lots of an adjuvanted influenza vaccine candidate and evaluate the safety of an adjuvanted influenza vaccine candidate versus Fluarix administered intramuscularly in elderly.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Jun 2023
Price :
$35
*
At a glance
- Drugs GSK 1247446A (Primary) ; Influenza virus vaccine
- Indications Influenza virus infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors GlaxoSmithKline; GSK
- 12 May 2019 This trial has been completed in UK as per European Clinical Trials Database record.
- 27 Oct 2008 Actual end date changed from Dec 2006 to Jul 2006 as reported by Clinicaltrials.gov
- 23 Oct 2008 Study end date changed from 1 Jul 2006 to 1 Dec 2006 as reported by ClinicalTrials.gov.